Inhibition of NADPH oxidase 4 attenuates lymphangiogenesis and tumor metastasis in breast cancer
Open Access
- 26 March 2021
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 35 (4) , e21531
Abstract
Lymphangiogenesis is thought to contribute to promote tumor cells to enter lymphatic vessels and plant at a secondary site. Endothelial cells are the cornerstone of the generation of new lymphatic vessels. NADPH oxidase 4 (Nox4) is the most abundant one of NADPH oxidases in endothelial cells and the most studied one in relevance with cancer. Our purpose is to analyze the relationship between Nox4 and lymphangiogenesis and find out whether the newborn lymphatic vessels lead to cancer metastasis. We first explored the expression of Nox4 in lymphatic endothelial cells of primary invasive breast tumors and human normal mammary glands using GEO databases and found that Nox4 was upregulated in primary invasive breast tumors samples. In addition, its high expression correlated with lymph node metastasis in breast cancer patients. Nox4 could increase the tube formation and lymphatic vessel sprouting in a three‐dimensional setting. In vivo, inhibition of Nox4 in 4T1 tumor‐bearing mice could significantly decrease the tumor lymphangiogenesis and metastasis. Nox4 may increase tumor lymphangiogenesis via ROS/ERK/CCL21 pathway and attract CCR7‐positive breast cancer cells to entry lymphatic vessels and distant organs. In conclusion, our results show that Nox4 is a factor that promotes lymphangiogenesis and is a potential target of antitumor metastasis.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2017PH055, ZR2019MH109, ZR2016HB11)
- National Natural Science Foundation of China (81601721)
This publication has 34 references indexed in Scilit:
- ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladderBMC Urology, 2011
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- NADPH oxidase 4 is an oncoprotein localized to mitochondriaCancer Biology & Therapy, 2010
- Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosisJournal of Experimental & Clinical Cancer Research, 2010
- Lymphangiogenesis: A new player in cancer progressionWorld Journal of Gastroenterology, 2010
- NADPH Oxidase 4 Contributes to Transformation Phenotype of Melanoma Cells by Regulating G2-M Cell Cycle ProgressionCancer Research, 2009
- Oxidative Stress Is Inherent in Prostate Cancer Cells and Is Required for Aggressive PhenotypeCancer Research, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- VEGF-C–induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sitesBlood, 2006
- Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancerBreast Cancer Research and Treatment, 2005